Reduced AMH levels after chemotherapy were shown in a trial on 170 premenopausal breast cancer patients aged ≤ 40 years who received taxane-anthracycline-based chemotherapy, indicating an increasing rate of ovarian damage in patients [25], with AMH level diminishing to < 0.1 ng/ml (range < 0.1–0.21 ng/ml) in most patients (98.6%) at four weeks after chemotherapy [25]. The gene discussed is AMH; the disease is breast cancer.